Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H25F4N3O4S.H3O4P |
Molecular Weight | 613.516 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OP(O)(O)=O.CCS(=O)(=O)C1=CC2=C(NC(C[C@](O)(CC(C)(C)C3=C(C=C(F)C=C3)C(N)=O)C(F)(F)F)=C2)C=N1
InChI
InChIKey=DPIBBVZDLOOJRM-FTBISJDPSA-N
InChI=1S/C23H25F4N3O4S.H3O4P/c1-4-35(33,34)19-8-13-7-15(30-18(13)11-29-19)10-22(32,23(25,26)27)12-21(2,3)17-6-5-14(24)9-16(17)20(28)31;1-5(2,3)4/h5-9,11,30,32H,4,10,12H2,1-3H3,(H2,28,31);(H3,1,2,3,4)/t22-;/m0./s1
Molecular Formula | C23H25F4N3O4S |
Molecular Weight | 515.521 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | H3O4P |
Molecular Weight | 97.9952 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:40:27 GMT 2023
by
admin
on
Sat Dec 16 11:40:27 GMT 2023
|
Record UNII |
DCS4MDS87R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DCS4MDS87R
Created by
admin on Sat Dec 16 11:40:27 GMT 2023 , Edited by admin on Sat Dec 16 11:40:27 GMT 2023
|
PRIMARY | |||
|
1198784-97-2
Created by
admin on Sat Dec 16 11:40:27 GMT 2023 , Edited by admin on Sat Dec 16 11:40:27 GMT 2023
|
PRIMARY | |||
|
49793273
Created by
admin on Sat Dec 16 11:40:27 GMT 2023 , Edited by admin on Sat Dec 16 11:40:27 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Official Title: Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers (Dose Range: 0.1 mg - 1500 mg). A Singleblind (Within Dose Groups), Randomised, Placebo-controlled Within Dose Groups, Single Rising Dose Phase I Study
Purpose: Investigation of safety and tolerability of BI 653048 H3PO4 following the administration of single rising doses of an aqueous solution in healthy male subjects
Pharmacokinetic and pharmacodynamic characteristics of BI 653048, including the investigation of dose proportionality
Investigation of relative bioavailability of capsules versus aqueous solution
|